dermavant®

CORPORATE FACT SHEET
Issued July 2021

Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant at-a-glance

- Clinical-stage biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, California and Raleigh-Durham, North Carolina

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage bio-pharmaceutical company focused on developing products that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company's robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively.

Management team

Todd Zavodnick
Chief Executive Officer

Philip M. Brown, MD, JD
Chief Medical Officer

Chris Chapman
Chief Commercial Officer

David Rubenstein, MD, PhD
Chief Scientific Officer

Michael Swartzburg
Chief Financial Officer

Christopher Van Tuyl, JD
General Counsel

Investor Relations Key Contact
Laurence Watts · laurence@gilmartinIR.com
Managing Director, Gilmartin Group LLC

To learn more,
visit **www.Dermavant.com**.

Dermavant has four product candidates addressing:

Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne



Excludes certain Asian territories

Key market data

Psoriasis: 8M patients in U.S.[1]

- $12.0B sales[2]
- $19.3B by 2026[2]
- Topical treatments are ~58% of U.S. Rxs[3]

Atopic dermatitis: 26M patients in U.S.[4]

- $1.8B sales[2]
- $5.7B by 2026[2]
- Topical treatments are ~97% of U.S. Rxs[3]

Vitiligo: 0.5% to 2% of global population[5]

- No FDA-approved therapies

Hyperhidrosis: 15.3M patients in U.S.[6]

- No FDA-approved systemic treatments

References: 1. National Psoriasis Foundation. **2.** Evaluate Pharma. **3.** IQVIA National Prescription Audit (NPA), October 2020. **4.** National Eczema Association. **5.** Bergqvist C, Ezzedine K. Vitiligo: A Review. *Dermatology*. 2020;236:571-592. doi: 10.1159/000506103. **6.** Doolittle, J. et al. *Arch Dermatol Res*. 2016;308:743-749; US Census.

Main Phone Number: 919-767-3277

Company locations:

Long Beach, California Office
Dermavant Sciences, Inc.
3780 Kilroy Airport Way, Suite 250
Long Beach, CA 90806

Raleigh-Durham, North Carolina Office
Dermavant Sciences, Inc.
3300 Paramount Parkway, Suite 150
Morrisville, NC 27560

Basel, Switzerland Office
Dermavant Sciences GmbH
Viaduktstrasse 8
4051 Basel